Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06813924
PHASE1

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

Sponsor: Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

The study aims to test if a new medicine called etavopivat potentially affects other medicines in healthy participants. The purpose of the study is to investigate whether the use of etavopivat affects the breakdown and metabolism of commonly used medicines in the body. During the study, participants will receive etavopivat and five different medicines that are already approved and available on the market, and which can be prescribed by doctors. These marketed medicines are called substrate drugs and they are: digoxin, pitavastatin, metformin, midazolam, and rosuvastatin. During a period of the study, participants will take 2 tablets of etavopivat daily for 10 consecutive days. The study will last for about 34 to 64 days.

Official title: An Open-Label, Fixed-Sequence Study to Evaluate the Effect of Etavopivat on the Single-Dose Pharmacokinetics of Midazolam, Digoxin, Rosuvastatin, Pitavastatin, and Metformin in Healthy Adult Participants

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

37

Start Date

2025-02-06

Completion Date

2025-05-27

Last Updated

2026-09-29

Healthy Volunteers

Yes

Interventions

DRUG

Etavopivat

Participants will receive a daily dose of etavopivat orally.

DRUG

Digoxin

Participants will receive a single dose of digoxin orally.

DRUG

Pitavastatin

Participants will receive a single dose of pitavastatin orally.

DRUG

Metformin

Participants will receive a single dose of metformin orally.

DRUG

Midazolam

Participants will receive a single dose of midazolam orally.

DRUG

Rosuvastatin

Participants will receive a single dose of rosuvastatin orally.

Locations (1)

ICON-Salt Lake City

Salt Lake City, Utah, United States